Mark Bunnage, D.Phil
Dr. Bunnage joined Vertex in 2016 as Senior Vice President and Site Head for Boston Research. He oversees preclinical research from project initiation through to the identification of new candidate medicines. His team works on a number of serious diseases, including alpha-1 antitrypsin deficiency, focal segmental glomerulosclerosis, and sickle cell disease.
Prior to joining Vertex, Dr. Bunnage spent 20 years at Pfizer, Inc., where he held a variety of roles within Medicinal Chemistry. From 1996 to 2011, Dr. Bunnage was based at Pfizer’s research site in the U.K. where he became Head of Medicinal Chemistry, Sandwich Laboratories. In 2011, he was appointed Vice President, Worldwide Medicinal Chemistry, and relocated to Cambridge, Massachusetts where he worked until 2016.
Dr. Bunnage studied chemistry at the University of Durham and conducted postgraduate research with Professor S G Davies at the University of Oxford. He then moved to The Scripps Research Institute in La Jolla, California to work with Professor K C Nicolaou as a NATO postdoctoral fellow.
Dr. Bunnage has broad interests in Drug Discovery and is an author or inventor on over 50 publications and patents. He is a Fellow of the Royal Society of Chemistry and a visiting Professor in Chemistry at the University of Oxford.